IO Biotech
The company develops off-the-shelf therapeutic cancer vaccines using its proprietary T-win technology platform. These vaccines are designed to modulate the tumor microenvironment by targeting and killing both tumor cells and immune-suppressive cells that express IDO1 and PD-L1. The primary target market includes patients with melanoma and other solid tumor types through combination therapy approaches.
Biotechnology
Oncology
Healthtech
Funding summary
- Total raised
- €127.0M
- Funding rounds
- 1
Investors in IO Biotech
Investors on record for IO Biotech. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like IO Biotech?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors